Advertisement
Advertisement
PVLA
Palvella Therapeutics, Inc. Common Stock
147.47
USDSponsored
+14.56
+10.95%
Oct 28, 15:59 UTC -4
Closed
After-Market
147.75
+0.28
+0.19%
Palvella Therapeutics, Inc. Common Stock (PVLA) Earnings
PVLA Earnings Reports
Positive Surprise Ratio
PVLA beat 22 of 39 last estimates.
56%
Next Report
Date of Next Report
Nov 17, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.82
Implied change from Q2 26 (Revenue/ EPS)
--
/+19.74%
Implied change from Q3 25 (Revenue/ EPS)
--
/+76.70%
Palvella Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, PVLA reported earnings of -1.52 USD per share (EPS) for Q2 26, missing the estimate of -1.18 USD, resulting in a -28.54% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.96% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -1.82 USD, with revenue projected to reach -- USD, implying an increase of 19.74% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Repligen Corp
Report Date
Oct 27, 2026 For Q3 26
Estimate
$0.46
Actual
$0.53
Surprise
+12.79%
Viking Therapeutics, Inc
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$1.08
Actual
-$1.55
Surprise
-42.55%
NeoGenomics, Inc.
Report Date
Oct 28, 2026 For Q3 26
Estimate
$0.05
Actual
$0.07
Surprise
+27.50%
argenx SE - ADR
Report Date
Oct 22, 2026 For Q3 26
Estimate
$8.19
Actual
$7.80
Surprise
-4.84%
Biogen Inc. Common Stock
Report Date
Oct 28, 2026 For Q3 26
Estimate
$2.01
Actual
$2.62
Surprise
+30.13%
QIAGEN N.V.
Report Date
Oct 21, 2026 For Q3 26
Estimate
$0.63
Actual
$0.65
Surprise
+2.43%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Oct 27, 2026 For Q3 26
Estimate
$0.02
Actual
$0.30
Surprise
+1,165.82%
MiMedx Group, Inc
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.01
Actual
-$0.01
Surprise
+26.47%
Nautilus Biotechnolgy, Inc. Common Stock
Report Date
Oct 27, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.12
Surprise
+15.97%
Vanda Pharmaceuticals Inc.
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.37
Surprise
+46.81%
FAQ
What were Palvella Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Palvella Therapeutics, Inc. Common Stock reported EPS of -$1.52, missing estimates by -28.54%, and revenue of $0.00, 0% as expectations.
How did the market react to Palvella Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 7.96%, changed from $140.78 before the earnings release to $151.99 the day after.
When is Palvella Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 17, 2026.
What are the forecasts for Palvella Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Palvella Therapeutics, Inc. Common Stock is expected to report EPS of -$1.82 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.